Janssen Redefines Clinical Trial Design by Leveraging Wearable Technology

Janssen Redefines Clinical Trial Design by Leveraging Wearable Technology

Shots:

  • Janssen is reimagining digital clinical trial design with the launch of a CHIEF-HF study. The study will evaluate Invokana (canagliflozin) vs PBO in patients aged ≥18yrs. with either preserved or reduced ejection fraction HF, with or without T2D
  • The CHIEF HF study will utilize personal smartphones and wearable devices to track patient outcomes via app-based clinical questionnaires and physical activity data logged by an app on the smartphone and actigraphy data from a wearable activity device, with no in-person clinical visits required
  • CHIEF-HF is the first-ever completely decentralized, mobile, indication-seeking study, design with the potential to bring faster & cost-effective therapies to the patients. The study plans to enroll ~1,900 participants in the US

Click here to­ read full press release/ article | Ref: Janssen | Image: Studioscalzi